ACTRN12621000171819招募中1 期
IMaging of cancer imMUNOtherapy targets with Positron Emission Tomography: Characterising PD-L1 with 89Zr- Durvalumab (MEDI4736)
Peter MacCallum Cancer Centre0 个研究点目标入组 5 人开始时间: 2021年2月18日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1. Written informed consent provided.
- •2. Female or male
- •3. Life expectancy greater than or equal to 12 weeks
- •4. Minimum age greater than or equal to 18 years, no maximum age.
- •5. Body weight >30kg
- •6.Patients with NSCLC and with advanced incurable disease, and with metastatic disease apparent on FDG-PET
- •7. Histopathology with PD-L1 positive tumour cells >25%. Although, in the metastatic setting >50% is the accepted cut-off, the threshold for Stage III patients remains poorly defined. A cut-off of >25% to broaden the eligibility criteria for enrolment is considered appropriate in this study
- •8. Subjects with an estimated glomerular filtration rate (eGFR) > 50ml/min as measured using the MDRD formula (Modification of Diet in Renal Disease).
- •9. Eastern Cooperative Group Oncology Group (ECOG) performance score of 0-2.
排除标准
- •1.Pregnant or breastfeeding females
- •2.Known sensitivity or allergy to anti-PD-L1 agents
- •3.Any serious medical condition which the investigator feels may interfere with the procedures or evaluations of the study
- •4.Patients unwilling or unable to comply with protocol or with a history of non-compliance or inability to grant informed consent
研究者
相似试验
尚未招募
Unknown
Imaging biomarkers of response to immunotherapy in patients with malignant mesotheliomaMesotheliomaCancer - Lung - MesotheliomaACTRN12623000632695The University of Western Australia40
招募中
不适用
Imaging biomarkers for immune checkpoint inhibitor treatment in patients with non-small cell lung cancerKCT0007153Samsung Medical Center100
已完成
不适用
Functional imaging for advanced cancer treatmentAdvanced cancerJPRN-UMIN000005128Biomedical Imaging Research Center, University of Fukui100
招募中
2 期
Imaging of tumour microenvironment in patients with oropharyngeal head and neck squamous cell carcinoma using RGD PET/CT imaging.mouth- and throat cavity tumoursOropharyngeal squamous cell carcinomas10027655NL-OMON47965Radiologie en Nucleaire Geneeskunde20
进行中（未招募）
1 期
Imaging of newly formed blood vessels in tumors of the mouth and throat cavityThe aim of this study is to assess differences in tumour microenvironment between HPV positive and HPV negative oropharyngeal head and neck squamous cell carcinoma using [68Ga]Ga-RGD2 PET/CT and perfusion CTMedDRA version: 20.0 Level: LLT Classification code 10031117 Term: Oropharyngeal squamous cell carcinoma stage III System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10031112 Term: Oropharyngeal squamous cell carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10031116 Term: Oropharyngeal squamous cell carcinoma stage II System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10031115 Term: Oropharyngeal squamous cell carcinoma stage I System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-001843-37-NLRadboud University Medical Center20